News
ADAG
2.510
-6.34%
-0.170
Adagene Begins Phase 1 Trial Of Muzastotug Plus INCA33890 In MSS Colorectal Cancer; Stock Up
NASDAQ · 3d ago
Adagene Is Maintained at Buy by Chardan Capital
Dow Jones · 3d ago
Adagene Price Target Maintained With a $9.00/Share by Chardan Capital
Dow Jones · 3d ago
Adagene doses first patient in muzastotug, INCA33890 combination study
TipRanks · 3d ago
Weekly Report: what happened at ADAG last week (1019-1023)?
Weekly Report · 5d ago
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX), Sarepta Therapeutics (SRPT) and Adagene (ADAG)
TipRanks · 10/19 10:30
Adagene Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Dow Jones · 10/19 10:27
HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $7 Price Target
Benzinga · 10/19 10:17
Weekly Report: what happened at ADAG last week (1012-1016)?
Weekly Report · 10/19 10:05
Weekly Report: what happened at ADAG last week (1005-1009)?
Weekly Report · 10/12 10:10
Weekly Report: what happened at ADAG last week (0928-1002)?
Weekly Report · 10/05 10:09
Analysts Have Conflicting Sentiments on These Healthcare Companies: Roche Holding AG (OtherRHHVF), Adagene (ADAG) and Inventiva (IVA)
TipRanks · 09/29 10:50
Weekly Report: what happened at ADAG last week (0921-0925)?
Weekly Report · 09/28 10:05
Adagene Announces Finance Executive Resignation Effective September 30, 2026
TipRanks · 09/25 21:01
Adagene Gains NMPA Clearance On Phase 1 For ADG138 In Solid Tumors, Set To Begin In Q4 '26
NASDAQ · 09/22 20:21
Adagene Wins NMPA IND Clearance for Novel HER2xCD3 T-Cell Engager ADG138
TipRanks · 09/22 12:27
Adagene announces China’s NMPA approved IND for ADG138
TipRanks · 09/22 12:05
China’s NMPA Approves Adagene’s IND Application For ADG138, Double-Masked HER2×CD3 Bispecific T Cell Engager Built On Proprietary SAFEbody Precision Masking Technology
Benzinga · 09/22 12:01
Weekly Report: what happened at ADAG last week (0914-0918)?
Weekly Report · 09/21 10:05
Adagene CEO Makes Bold Insider Move With Fresh Stock Purchase
TipRanks · 09/18 02:05
More
Webull provides a variety of real-time ADAG stock news. You can receive the latest news about Adagene Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ADAG
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.